Search Results

Nora Pharma, a Canadian pharmaceutical company, has received approval for its first Biosimilar product.

Sunshine Biopharma Inc. is happy to announce that its wholly owned generic pharmaceutical subsidiary, Nora Pharma, has received approval for its first Biosimilar product.

Zai Lab Limited announced that the final overall survival data from the Phase 3 randomized, double-blind, placebo-controlled NORA study evaluating ZEJULA® in Chinese patients with platinum-sensitive recurrent ovarian cancer will be shared in oral presentations at the 2024 Congress of the European Society of Gynaecological Oncology and the 2024 Society for Gynecologic Oncology Annual Meeting on Women’s Cancer.

An appreciation for practicality, independent thinking and patient care can help disrupt the bureaucracy of Big Pharma.

Sunshine Biopharma Inc. today announced that it has completed the acquisition of all the outstanding shares of Nora Pharma Inc., effective immediately.

Athira Pharma will cut about 49 positions, including two people in the C-suite. The announcement follows the company’s disappointing results for its investigational Alzheimer’s therapy.

Astellas Pharma’s new life sciences center houses its first U.S.-based SakuLab, an incubator space for external partners, as well as its engineered small molecules unit.

Not all licensing deals are successful. Here, BioSpace examines a few noteworthy assets that Big Pharma returned in the last 12 months.

Large pharmaceutical companies were out in force at this week’s 2024 Cell & Gene Meeting on the Mesa, as they look to expand their presence in the industry.

ARS Pharma’s neffy on Friday became the first FDA-approved nasal spray to address severe allergic reactions, including those that might lead to life-threatening anaphylaxis.